Head to Head Review: SAB Biotherapeutics (NASDAQ:SABS) and Outlook Therapeutics (NASDAQ:OTLK)

Outlook Therapeutics (NASDAQ:OTLK) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Risk & Volatility

Outlook Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Outlook Therapeutics and SAB Biotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Outlook Therapeutics	0	0	7	0	3.00
SAB Biotherapeutics	0	0	5	0	3.00

Outlook Therapeutics presently has a consensus target price of $48.20, indicating a potential upside of 875.71%. SAB Biotherapeutics has a consensus target price of $12.40, indicating a potential upside of 392.06%. Given Outlook Therapeutics’ higher probable upside, analysts plainly believe Outlook Therapeutics is more favorable than SAB Biotherapeutics.

Earnings & Valuation

This table compares Outlook Therapeutics and SAB Biotherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Outlook Therapeutics	N/A	N/A	-$58.98 million	($11.41)	-0.43
SAB Biotherapeutics	$2.24 million	10.38	-$42.19 million	N/A	N/A

SAB Biotherapeutics has higher revenue and earnings than Outlook Therapeutics.

Profitability

This table compares Outlook Therapeutics and SAB Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Outlook Therapeutics	N/A	N/A	-160.88%
SAB Biotherapeutics	-1,450.14%	-94.04%	-65.68%

Insider & Institutional Ownership

11.2% of Outlook Therapeutics shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 3.4% of Outlook Therapeutics shares are owned by company insiders. Comparatively, 26.5% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

About Outlook Therapeutics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.